Literature DB >> 16697514

Differential polyamine analogue effects in four human breast cancer cell lines.

C Martina Holst1, Benjamin Frydman, Laurence J Marton, Stina M Oredsson.   

Abstract

Polyamine analogues have demonstrated anti-tumour activity in a number of solid tumour models. In the present study we compared the cytotoxicities of three polyamine analogues against four breast cancer cell lines. All cell lines are derived from tumours of women with breast cancer and, although we are sampling just a small number of tumours, they represent a spectrum of the genetic plethora of breast cancers. Cytotoxicity, over a dose range from 0.1 to 100 microM, was evaluated with three different cytotoxicity assays performed in 96-well plates. Comparing the effects of the analogues on polyamine pools with data from the cytotoxicity assays indicates that there was not a direct correlation between polyamine pool depletion and cytotoxicity. Flow cytometry was used to investigate analogue-induced cell death as measured by the appearance of a sub-G(1) peak. Induction of cell death by the analogues differed in the cell lines, however, cell death when induced was apoptotic, as demonstrated by detection of apoptotic bodies with immunofluorescence microscopy of propidium iodide-stained nuclei. Comparing the flow cytometry-derived data and the data from the cytotoxicity assays reveals that the analogues exert their effects by inhibiting cell growth and/or inducing cell death.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16697514     DOI: 10.1016/j.tox.2006.03.009

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  9 in total

1.  A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors.

Authors:  Tracy Murray Stewart; Apurva A Desai; Michael L Fitzgerald; Laurence J Marton; Robert A Casero
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-23       Impact factor: 3.333

2.  Therapeutic evaluation of polyamine analogue drug candidates against Enterocytozoon bieneusi in a SCID mouse model.

Authors:  Xiaochuan Feng; Venudhar K Reddy; Harriet Mayanja-Kizza; Louis M Weiss; Laurence J Marton; Saul Tzipori
Journal:  Antimicrob Agents Chemother       Date:  2009-03-16       Impact factor: 5.191

3.  Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047.

Authors:  Natalia A Ignatenko; Hagit F Yerushalmi; Ritu Pandey; Karen L Kachel; David E Stringer; Laurence J Marton; Eugene W Gerner
Journal:  Cancer Genomics Proteomics       Date:  2009 May-Jun       Impact factor: 4.069

4.  Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism.

Authors:  Tracy Murray-Stewart; Christin L Hanigan; Patrick M Woster; Laurence J Marton; Robert A Casero
Journal:  Mol Cancer Ther       Date:  2013-08-13       Impact factor: 6.261

5.  Norspermidine and novel Pd(II) and Pt(II) polynuclear complexes of norspermidine as potential antineoplastic agents against breast cancer.

Authors:  Tânia Magalhães Silva; Sara Andersson; Sunil Kumar Sukumaran; Maria Paula Marques; Lo Persson; Stina Oredsson
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

6.  Effect of polyamines and synthetic polyamine-analogues on the expression of antizyme (AtoC) and its regulatory genes.

Authors:  Panagiota S Filippou; Efthimia E Lioliou; Christos A Panagiotidis; Constantinos M Athanassopoulos; Thomas Garnelis; Dionyssios Papaioannou; Dimitrios A Kyriakidis
Journal:  BMC Biochem       Date:  2007-01-15       Impact factor: 4.059

7.  Biochemical evaluation of the anticancer potential of the polyamine-based nanocarrier Nano11047.

Authors:  Tracy Murray-Stewart; Elena Ferrari; Ying Xie; Fei Yu; Laurence J Marton; David Oupicky; Robert A Casero
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

8.  A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.

Authors:  Wen-Lin Kuo; Debopriya Das; Safiyyah Ziyad; Sanchita Bhattacharya; William J Gibb; Laura M Heiser; Anguraj Sadanandam; Gerald V Fontenay; Zhi Hu; Nicholas J Wang; Nora Bayani; Heidi S Feiler; Richard M Neve; Andrew J Wyrobek; Paul T Spellman; Laurence J Marton; Joe W Gray
Journal:  BMC Med       Date:  2009-12-14       Impact factor: 8.775

9.  A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.

Authors:  Tracy Murray Stewart; Daniel Von Hoff; Michael Fitzgerald; Laurence J Marton; Carlos H Roberto Becerra; Thomas E Boyd; Paul R Conkling; Lawrence E Garbo; Robert M Jotte; Donald A Richards; David A Smith; Joe J Stephenson; Nicholas J Vogelzang; Hillary H Wu; Robert A Casero
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-19       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.